Clinical Trials Logo
  1. Home
  2. Carcinoma, Renal Cell
  3. NCT06111560
  4. Details
NCT06111560 Clinical Trial

Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma

Carcinoma, Renal Cell Clinical Trial

Official title:
Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06111560
Other study ID # IIT-2023-282
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2012
Est. completion date February 1, 2022

Study information
Verified date October 2023
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with renal cell carcinoma who were admitted to the First Affiliated Hospital of Sun Yat-sen University from February 1, 2021, to February 1, 2022, and met the following inclusion and exclusion criteria were collected. Clinical factors influencing the prognosis of enrolled patients were retrospectively analyzed, and a predictive system was established based on this. (Inclusion criteria: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center. Exclusion criteria:a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up.)

Recruitment information / eligibility
Status Completed
Enrollment 160
Est. completion date February 1, 2022
Est. primary completion date February 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: a: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center Exclusion Criteria: a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• We do not have any interventions. This study is based on obseravation.
observational retrospective study without any interventions

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Sun Yat-sen University

Outcome
Type Measure Description Time frame Safety issue
Primary Tumor progression medical imaging examinations showed tumor progression 12 months
See also
  Status Clinical Trial Phase
Completed NCT02248389 - Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses Phase 1
Completed NCT03900364 - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy N/A
Completed NCT00158782 - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients Phase 1
Completed NCT03109015 - Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing Phase 2
Completed NCT00363194 - A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients Phase 1
Completed NCT01012011 - Regulatory Post Marketing Surveillance Study on Nexavar® N/A
Completed NCT00842790 - Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging N/A
Completed NCT00529802 - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer Phase 2
Completed NCT00338884 - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer Phase 2
Completed NCT00356460 - Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma Phase 1
Completed NCT00387764 - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Phase 3
Completed NCT00095186 - Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma Phase 2
Completed NCT00079612 - Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer Phase 2
Completed NCT00043368 - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) Phase 2
Active, not recruiting NCT04489771 - A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Phase 2
Completed NCT00516672 - Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors Phase 1
Withdrawn NCT05104905 - A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma Phase 1/Phase 2
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT03111901 - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Phase 1/Phase 2
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1